Influx Flow Cytometer

流入流式细胞仪

• 批准号: 8447644
• 负责人: FREDERIC Ira PREFFER
• 金额: $ 60万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-06-20 至 2015-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8447644
• 关键词: Age; Boston; Budgets; Cells; Cellular biology; Clinical; Communicable Diseases; Communities; Cytometry; Engineering; Environment; Financial Support; Flow Cytometry; Fluorescence; Funding; Gases; General Hospitals; Genetic; Grant; Hospital Administration; Hospital Units; Hospitals; Human; Immunology; Ions; Laboratories; Laboratory Research; Lasers; Massachusetts; Molecular Biology; National Center for Research Resources; Optical Instrument; Pathology; Research; Research Personnel; Resources; Sorting - Cell Movement; Stem Cell Research; Translational Research; United States National Institutes of Health; Universities; Work; base; design; experience; improved; instrument; instrumentation; multidisciplinary; oncology; operation

DESCRIPTION (provided by applicant): NIH funds are requested to purchase a BD Influx cell sorter that will be placed in the PI's 870 ft2 research laboratory at Massachusetts General Hospital (MGH) in Boston. The Influx is a 6- laser instrument that is a vastly improved, refined and a far more powerful cell sorter than that it will replace, the FACS Vantage. The Vantage was initially designed in the 1990s and purchased by the PI with NCRR funds in 2000; two of the four ion-gas lasers on this instrument's optical bench are over 25 years old. Due to its chronologic age, the Vantage is increasingly difficult to maintain. Far more critically, from an engineering and technological perspective it no longer offers the necessary fluorescence sensitivity, cellular throughput and high capacity 6-way sorting ability that our user base requires. Also, a rapidly increasing translational research emphasis has accentuated the need for safe, bio-contained sorting capabilities of human cells beyond the capacity of our current sorting platform. Thus, the requested Influx will be configured additionally with a Baker class II Type A2 certified HEPA filtered biosafety hood that will provide far greater protection to the operator and local environment. The requested Influx will be placed in the PI's well established Flow Cytometry Core which has been in successful operation for almost 30 years. A wide variety of studies related to cell biology, immunology, genetics, molecular biology, infectious disease, oncology and stem cell research will all benefit from the placement of this instrumentation in the PI's facility. The PI has an established track record in utilizing polychromatic cytometry for both research and clinical work and documents that the requested instrument will provide an essential resource to the needs of the research user base at MGH. This instrument will initially serve a multidisciplinary group of 28 primary investigators from 9 departments and numerous MGH Units, representing 78 NIH funded grants totaling over 44.8 million dollars. The Influx will further benefit the entire research community at MGH, who presently lack a modern cell-sorter for their NIH funded work. The entire hospital of approximately 1000 PI's has a NIH budget of about $325 million dollars. The PI has been part of the MGH research community since 1982, and his laboratory has been the only one easily available to all investigators at MGH. The laboratory has a highly skilled operator, who along with the PI collectively represents almost 60 years of well-documented experience in flow cytometry. The laboratory has the financial support of both the Department of Pathology and MGH administration and approval of the University Biosafety office for the projects outlined in this submission.

描述（由申请人提供）：请求 NIH 提供资金购买 BD Influx 细胞分选机，将其放置在 PI 位于波士顿马萨诸塞州综合医院 (MGH) 的 870 平方英尺研究实验室中。 Influx 是一款 6 激光仪器，与它将取代的 FACS Vantage 相比，它是一款经过极大改进、改进且功能更强大的细胞分选仪。 Vantage 最初设计于 20 世纪 90 年代，2000 年由 PI 用 NCRR 资金购买；该仪器光具座上的四个离子气体激光器中有两个已经超过 25 年。由于其实际年龄，Vantage 的维护越来越困难。更重要的是，从工程和技术的角度来看，它不再提供我们的用户群所需的必要的荧光灵敏度、细胞通量和高容量 6 路分选能力。此外，快速增长的转化研究重点强调了对人类细胞安全、生物分选能力的需求，超出了我们当前分选平台的能力。因此，所要求的 Influx 将额外配置贝克 II 级 A2 型认证的 HEPA 过滤生物安全罩，为操作员和当地环境提供更大的保护。所请求的 Influx 将被放置在 PI 完善的流式细胞术核心中，该核心已成功运行近 30 年。与细胞生物学、免疫学、遗传学、分子生物学、传染病、肿瘤学和干细胞研究相关的各种研究都将受益于在 PI 设施中放置该仪器。该 PI 在利用多色细胞术进行研究和临床工作方面拥有良好的记录，并证明所需的仪器将为满足 MGH 研究用户群的需求提供重要资源。该仪器最初将为来自 9 个部门和众多 MGH 单位的 28 名主要研究人员组成的多学科小组提供服务，代表 78 项 NIH 资助的赠款，总额超过 4480 万美元。此次涌入将进一步使 MGH 的整个研究界受益，他们目前缺乏现代细胞分选仪来开展 NIH 资助的工作。整个医院约有 1000 名 PI，NIH 的预算约为 3.25 亿美元。自 1982 年以来，这位 PI 一直是 MGH 研究团体的一部分，他的实验室是 MGH 唯一一个可供所有研究人员轻松使用的实验室。该实验室拥有一名技术精湛的操作员，他们与 PI 一起拥有近 60 年流式细胞术方面的丰富经验。该实验室得到了病理学系和麻省总医院管理部门的财政支持，并获得了大学生物安全办公室对本申请中概述的项目的批准。